A Study Evaluating MM-310 in Patients With Solid Tumors
NCT ID: NCT03076372
Last Updated: 2018-02-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
34 participants
INTERVENTIONAL
2017-02-22
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors
NCT01591356
A Study of DS3610a in Participants With Advanced Solid Tumor
NCT07159126
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
NCT00385177
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
NCT04721015
Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies
NCT00703170
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MM-310 monotherapy
MM-310 will be administered by IV infusion over 90 minutes on the first day of each 21 day cycle.
MM-310
MM-310
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MM-310
MM-310
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Urothelial carcinoma
* Gastric/gastroesophageal junction/esophageal carcinoma (G/GEJ/E)
* Squamous Cell Carcinoma of the Head and neck (SCCHN)
* Ovarian cancer
* Pancreatic ductal adenocarcinoma (PDAC)
* Prostate adenocarcinoma (PAC)
* Non-small cell lung cancer (NSCLC)
* Small cell lung cancer (SCLC)
* Triple negative breast cancer (TNBC)
* Endometrial carcinoma
* Soft tissue sarcoma subtypes except GIST, desmoid tumors and pleomorphic rhabdomyosarcoma
* Able to provide informed consent, or have a legal representative able and willing to do so
* ≥ 18 years of age
* Availability of a cancerous lesion amenable to biopsy and willing to undergo a pre-treatment biopsy
* ECOG Performance Status of 0 or 1
* Adequate bone marrow reserve as evidenced by:
* ANC \> 1,500/µl (unsupported by growth factors) and
* Platelet count \> 100,000/µl
* Hemoglobin \> 9 g/dL
* Patients must have adequate coagulation function as evidenced by prothrombin time (PT), activated partial thromboplastin time (aPTT) and international normalized ratio (INR) within normal institutional limits
* Adequate hepatic function as evidenced by:
* Serum total bilirubin ≤ ULN
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN.
* Alkaline phosphatase ≤ 2.5 x ULN, unless the elevated alkaline phosphatase is due to bone metastasis.
* In case alkaline phosphatase is \>2.5 x ULN patients are eligible for inclusion if aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 1.5 x ULN
* Adequate renal function as evidenced by a serum/plasma creatinine \< 1.5 x ULN
* Recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy to CTCAE v4.03 grade 1, baseline or less, except for alopecia
* Women of childbearing potential or fertile men and their partners must be willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 6 months following the last dose of MM-310.
Exclusion Criteria
* Pregnant or lactating
* Treatment with systemic anticoagulation (e.g. warfarin, heparin, low molecular weight heparin, anti-Xa inhibitors, etc.) except aspirin
* Any evidence of hematemesis, melena, hematochezia, ≥ grade 2 hemoptysis, or gross hematuria
* Any history of hereditary bleeding disorders
* Presence of an active infection or with an unexplained fever \> 38.5°C during screening visits or on the first scheduled day of dosing, which in the investigator's opinion might compromise the patient's participation in the trial or affect the study outcome. At the discretion of the investigator, patients with tumor fever may be enrolled
* Known CNS metastases
* Known hypersensitivity to the components of MM-310, or docetaxel
* Prior treatment with MM-310
* Received treatment, within 28 days or 5 half-lives, whichever is shorter, prior to the first scheduled day of dosing, with any investigational agents that have not received regulatory approval for any indication or disease state and all prior clinically significant treatment related toxicities have resolved to Grade 1 or baseline
* Received other recent antitumor therapy including any standard chemotherapy or radiation within 14 days (or have not yet recovered from any actual toxicities of the most recent therapy) prior to the first scheduled dose of MM-310
* Received any anti-cancer drug known to have anti-VEGF/VEGFR activity within a period of 5 half-lives of this drug (e.g. 100 days for bevacizumab, 75 days for ramucirumab) prior to the first scheduled dose of MM-310
* Clinically significant cardiac disease, including: NYHA Class III or IV congestive heart failure, unstable angina, acute myocardial infarction within six months of planned first dose, arrhythmia requiring therapy (including torsades de pointes, with the exception of extrasystoles, minor conduction abnormalities, or controlled and well treated chronic atrial fibrillation)
* Patients who are not appropriate candidates for participation in this clinical study for any other reason as deemed by the investigator
* Patients who received organ or allogeneic bone marrow or peripheral blood stem cell transplants
* Chronic use of corticosteroids more than 10mg daily prednisone equivalent during the past 4 weeks prior to planned start of MM-310
* Concomitant use of strong inhibitors of CYP3A
* Patients with peripheral neuropathy of grade 2 or higher
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merrimack Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vasileios Askoxylakis, MD, PhD
Role: STUDY_DIRECTOR
Merrimack
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Honor Health
Scottsdale, Arizona, United States
University California San Francisco
San Francisco, California, United States
Mayo Clinic
Rochester, Minnesota, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Duke University
Durham, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Huang ZR, Tipparaju SK, Kirpotin DB, Pien C, Kornaga T, Noble CO, Koshkaryev A, Tran J, Kamoun WS, Drummond DC. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs. J Control Release. 2019 Sep 28;310:47-57. doi: 10.1016/j.jconrel.2019.08.006. Epub 2019 Aug 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MM-310-01-01-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.